Top-line results from Aerie Pharmaceuticals’ AR-13324 Phase 2a study on glaucoma
Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.